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Temozolomide-Associated Bronchiolitis Obliterans Organizing 
Pneumonia Successfully Treated with High-Dose Corticosteroid 
Temozolomide is an oral alkylating agent with clinical activity against glioblastoma 
multiforme (GM). It is generally well-tolerated and has few pulmonary side effects. We 
report a case of temozolomide-associated brochiolitis obliterans organizing pneumonia 
(BOOP) requiring very high-dose corticosteroid treatment. A 56-yr-old woman presented 
with a 2-week history of exertional dyspnea. For the treatment of GM diagnosed 4 months 
previously, she had undergone surgery followed by chemoradiotherapy, and then planned 
adjuvant chemotherapy with temozolomide. After the 1st cycle, progressive dyspnea was 
gradually developed. Chest radiograph showed diffuse patchy peribronchovascular ground-
glass opacities in both lungs. Conventional dose of methylprednisolone (1 mg/kg/day) was 
begun for the possibility of BOOP. Although transbronchial lung biopsy findings were 
compatible with BOOP, the patient’s clinical course was more aggravated until hospital day 5. 
After the dose of methylprednisolone was increased (500 mg/day for 5 days) radiologic 
findings were improved dramatically.
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CASE REPORT
Respiratory Diseases
INTRODUCTION
Several medications are associated with organizing pneumonia, 
and bronchiolitis obliterans organizing pneumonia (BOOP) (1). 
Because the BOOP represents an inflammatory response of the 
lung, it can be generally reversed by causative drug cessation 
and/or corticosteroid therapy. Temozolomide is a new alkylat-
ing agent with clinical activity against glioblastoma multiforme. 
It is a generally well-tolerated oral agent with mild pulmonary 
side effects. In a phase II trial for patients with recurrent or pro-
gressive brain metastases from a variety of solid tumors, grade 3 
pneumonitis was developed in two cases (2), and there has been 
only one report of temozolomide-associated organizing pneu-
monitis until now (3). We herein report a case of temozolomide-
associated BOOP that required very high-dose corticosteroid 
treatment. 
CASE DESCRIPTION
A 56-yr-old woman presented with a 2-week history of dyspnea. 
After being diagnosed 4 months before presentation as having 
glioblastoma multiforme, the patient had undergone craniec-
tomy and tumor removal followed by radiotherapy (180 cGy, 33 
fractions) combined with low-dose (75 mg/m
2/day) temozolo-
mide for 6 weeks. The patient was then planned to receive adju-
vant chemotherapy with temozolomide (200 mg/m
2) taken dai-
ly for 5 days every 4 weeks. After the 1st cycle, respiratory symp-
toms with progressive dyspnea and nonproductive cough de-
veloped. The patient denied fever, any chest pain, sputum pro-
duction, or hemoptysis. The patient had never smoked and de-
nied taking any herbal or over-the-counter medications. Con-
comitant medications used were valproated sodium (Depakin
®) 
and acetyl-L-carnitine (Nicetile
®). The patient’s clinical history 
was negative for any other disease except glioblastoma.
  On physical examination, the patient was found to have a 
body temperature of 36.5°C, a blood pressure of 130/80 mmHg, 
a heart rate 88 beats/min, and a respiratory rate of 22 breaths/
min. After receiving 2 L/min of oxygen via nasal prong, the pa-
tient had an oxygen saturation of 95%. Auscultation of the lungs 
revealed some inspiratory crackles in both lung bases. The heart 
rate was regular without evidence of cardiac murmur, and find-
ings on the remainder of the physical examination were unre-
markable. Electrocardiogram showed normal sinus rhythm and 
there was no ventricular dysfunction in echocardiography. Lab-
oratory findings were within normal range with creatinine 0.9 
mg/dL, albumin 3.1 g/dL, leukocyte counts being 4,200/μL and 
eosinophil counts being 270/μL. There was no proteinuria or 
hematuria in urinalysis. Chest radiograph at admission showed Kim T-O, et al.  •  Temozolomide-Associated BOOP
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diffuse bilateral interstitial infiltrates (Fig. 1A). Computed to-
mography (CT) revealed diffuse patchy peribronchovascular 
ground-glass opacities and fine reticulations in both lungs (Fig. 
2A, B). Bronchoalveolar lavage (BAL) and transbronchial lung 
biopsy samples were taken from the right middle and lower 
lobes. BAL revealed leukocyte numbers of 215/μL (neutrophils 
22%, lymphocytes 45%, macrophages 33%). The biopsy speci-
mens showed peribronchial thickening and numerous intraal-
veolar fibrous plugs, and thickening alveolar septa by inflam-
matory cells, consistent with BOOP (Fig. 3). Blood, sputum, bron-
chial washing, and BAL culture results for common bacteria, 
acid-fast bacilli, and viruses (including novel influenza H1N1) 
were all negative. 
  We started antibiotics (ceftriaxone and clarythromycin) and 
oseltamivir empirically from the 1st day on admission. After per-
forming a chest CT, drug-induced BOOP was suspected, and the 
decision was made to discontinue temozolomide and start meth-
ylprednisolone (1 mg/kg/day). But, the patient’s dyspnea be-
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Fig. 1. Serial radiographic changes of the patient. Chest radiography at admission (A) shows multiple bilateral patchy nodular and interstitial opacities in both lungs. The con-
solidations are more aggravated at 5th hospital day (B). After high-dose corticosteroid treatment, the lesions are improved at 21st hospital day (C) and outpatient clinic exami-
nation (D).Kim T-O, et al.  •  Temozolomide-Associated BOOP
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Fig. 2. Chest computed tomography (CT) at admission (A, B) shows diffuse patchy and nodular peribronchovascular ground-glass opacities and fine reticulations with mild pa-
renchymal distorsion in both lungs. CT acquired on the 5th hospital day (C, D) reveals increased extent and density of ground-glass opacities with aggravated parenchymal dis-
torsion and traction bronchiectatic changes in both lungs. Moderate amount of pleural effusion is also observed.
came more aggravated and a follow-up chest CT (Fig. 2C, D) 
showed aggravated bilateral pulmonary infiltrations and both 
pleural effusion. On 5th day of admission, the pathological result 
was diagnostic of BOOP, so we increased the dose of methylpred-
nisolone (500 mg/day for 5 days and then gradually tapered) 
for this rapidly progressive drug-induced BOOP case. Thereaf-
ter, the patient’s symptoms and radiologic findings improved 
dramatically (Fig. 1C, D). The patient was discharged at the 23rd 
hospital day without recurrent attack.
DISCUSSION
To our knowledge, this is the first case of pathologically proven 
temozolomide-associated BOOP requiring high-dose cortico-
steroid therapy. Temozolomide is a second-generation oral al-
kylating agent that is mainly used in the treatment of glioblasto-
ma multiforme, anaplastic astrocytoma, and metastatic mela-
noma. The drug has a favorable side effect and is generally well-
tolerated. Adverse reactions are mostly hematologic, usually con-Kim T-O, et al.  •  Temozolomide-Associated BOOP
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Fig. 3. Pathology of transbronchial lung biopsy. Myxoid fibroblastic plugs are shown 
within intra-alveolar spaces (H&E, × 40).
sisting of thrombocytopenia and neutropenia. Although mild 
respiratory symptoms have been described, pulmonary toxicity 
that requires discontinuation of therapy is very rare. Temozolo-
mide-associated organizing pneumonitis was first reported in 
2007 (3). In that case, the patient’s condition was improved by a 
conventional dose of prednisone (1 mg/kg/day), unlike our case. 
  An increasing number of drugs are recognized as causing lung 
injury and the spectrum of their adverse effects is widening. In 
addition, new antineoplastic agents and regimens are constant-
ly being added to the list of available treatments for cancer pa-
tients. Since more patients are being treated with these agents, 
the frequency of drug-induced pulmonary toxicity is increasing 
(4). However, a definitive diagnose as drug-induced pulmonary 
toxicity is difficult. It is important to understand the time course 
of the disease and suspected drug medication timing, as well as 
to exclude other possible diagnoses, especially infections. The 
responses to discontinuation of the drug and to corticosteroid 
treatment are also helpful. In this case, respiratory symptoms 
were developed after first cycle of high-dose temozolomide and 
we could not find the evidence of infection or other specific 
medication history. In addition, pathologically proven BOOP 
was completely resolved by high-dose corticosteroid treatment. 
Therefore this case meets the criteria of drug-induced BOOP.
  BOOP may be classified into three categories according to its 
cause: BOOP of determined cause; BOOP of undetermined cause 
but occurring in a specific and relevant context; and cryptogenic 
(idiopathic) organizing pneumonia (5). The most common cause 
of BOOP is idiopathic, and drug-related BOOP is relatively rare. 
Several classes of medications cause the BOOP, including anti-
microbials, anticancer agents, cardiac agents, and anti-inflamma-
tory agents. Until now, various anticancer agents such as bleo-
mycin, busulphan, doxorubicin, methotrexate, mitomycin-C 
and docetaxel have been reported in the etiology of BOOP (1, 6). 
  Corticosteroids are the mainstay of treatment for any cause 
of BOOP. More than 80% of patients with BOOP show rapid and 
complete resolution of the disease when medicated using ste-
roids, although relapse can occur as the dose is reduced. The dos-
age is generally 1 mg/kg/day for 1-3 months, and then it should 
be gradually tapered for a total of 1 yr duration. A shorter 6-month 
course may be sufficient in certain situations (7). However, in 
some cases, patients present with a more aggressive clinical 
course with a rapidly progressive disease that is unresponsive 
to corticosteroids and which is associated with a high mortality 
(8). In corticosteroid-resistant situations, cyclophosphamide as 
adjunctive therapy has been used to treat BOOP (8), and other 
immunosuppressive agents such as azathioprine and cyclospo-
rine A are also effective (8, 9). As another treatment method, very 
high dose corticosteroid therapy (methylprednisolone 125-250 
mg every 6 hr IV for 3-5 days) has been suggested (10); we ap-
plied this strategy. Our patient has been receiving a tapered 
dose of corticosteroid for 6 months without any symptomatic 
or radiological recurrence.
  In conclusion, rapidly progressive BOOP has a fulminant 
course with considerable morbidity and mortality. As described 
in our case, early institution of very high-dose corticosteroid 
therapy should be considered if drug-induced BOOP does not 
respond to conventional dose corticosteroid treatment. 
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